# US 2013/0280212 A1 · Inhibitors of cytochrome p450

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280212 A1
- Document ID: US20130280212A1
- Status: Published application
- Kind: A1
- Application number: 13/996,174
- Filed: 2011-12-20
- Published: 2013-10-24
- Earliest claimed: 2010-12-21
- Assignees: Gilead Sciences, Inc.
- Inventors: Manoj C. Desai; Hongtao Liu; Lianhong Xu; Hong Ye
- Web page: https://patentgrep.com/patent/US20130280212A1

## CPC

- C07D 277/24: Radicals substituted by oxygen atoms
- A61K 31/426: 1,3-Thiazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application provides for a compound of formula (I), or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional therapeutic agent.

## Claims

### Claim 1

A compound of formula I:
wherein:
A1 is (C1-C6)alkyl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, (C3-C6)carbocyclyl(C1-C6)alkyl or heterocyclyl(C1-C6)alkyl, wherein any (C1-C6)alkyl of A1 is optionally substituted with one or more Z1 groups and wherein any aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, (C3-C6)carbocyclyl(C1-C6)alkyl or heterocyclyl(C1-C6)alkyl of A1 is optionally substituted with one or more Z2 groups;
A2 is (C1-C6)alkyl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, (C3-C6)carbocyclyl(C1-C6)alkyl or heterocyclyl(C1-C6)alkyl, wherein any (C1-C6)alkyl of A2 is optionally substituted with one or more Z1 groups and wherein any aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, (C3-C6)carbocyclyl(C1-C6)alkyl or heterocyclyl(C1-C6)alkyl of A2 is optionally substituted with one or more Z2 groups;
X is selected from the group consisting of R1aOC(O)—, R1bC(O)—, R1a(Ra)NC(O)—, R1bS(O)2— and R1a(Ra)NS(O)2—;
Y is —C(O)O— or —C(O)NRb—;
R1a is (C1-C8)alkyl, (C3-C6)carbocyclyl, aryl or aryl(C1-C6)alkyl, wherein any (C1-C8)alkyl of R1a is optionally substituted with one or more Z3 groups and wherein any (C3-C6)carbocyclyl, aryl or aryl(C1-C6)alkyl of R1a is optionally substituted with one or more Z4 groups;
R1b is (C1-C8)alkyl, (C3-C6)carbocyclyl, aryl, aryl(C1-C6)alkyl, heteroaryl, heteroaryl(C1-C6)alkyl, heterocyclyl or heterocyclyl(C1-C6)alkyl, wherein any (C1-C8)alkyl of R1b is optionally substituted with one or more Z3 groups and wherein any (C3-C6)carbocyclyl, aryl, aryl(C1-C6)alkyl, heteroaryl, heteroaryl(C1-C6)alkyl, heterocyclyl or heterocyclyl(C1-C6)alkyl of R1b is optionally substituted with one or more Z4 groups;
R2 is selected from the group consisting of H, (C1-C6)alkyl, (C3-C6)carbocyclyl, (C3-C6)carbocyclyl(C1-C6)alkyl- and aryl(C1-C6)alkyl;
R3 is selected from the group consisting of H, (C1-C6)alkyl, (C3-C6)carbocyclyl, C3-C6)carbocyclyl(C1-C6)alkyl- and aryl(C1-C6)alkyl;
R4 is aryl, aryl(C1-C6)alkyl, heteroaryl, heteroaryl(C1-C6)alkyl, heterocyclyl or heterocyclyl(C1-C6)alkyl, wherein any aryl, aryl(C1-C6)alkyl, heteroaryl, heteroaryl(C1-C6)alkyl, heterocyclyl or heterocyclyl(C1-C6)alkyl of R4 is optionally substituted with one or more Z5 groups;
each Z1 is independently selected from OH, oxo, halogen, OCF3, CN, —O(C1-C6)alkyl, S(C1-C6)alkyl, SO(C1-C6)alkyl, S(O)2(C1-C6)alkyl, —NRcRd, —NRiC(O)Rj and —NRiS(O)2Rj;
each Z2 is independently selected from OH, oxo, halogen, CF3, OCF3, NO2, CN, (C1-C6)alkyl, —O(C1-C6)alkyl, S(C1-C6)alkyl, SO(C1-C6)alkyl, S(O)2(C1-C6)alkyl, —NRcRd, —NRiC(O)Rj and —NRiS(O)2Rj;
each Z3 is independently selected from OH, halogen, CN, —O(C1-C6)alkyl, and —NReRf;
each Z4 is independently selected from OH, halogen, CF3, OCF3, NO2, CN, (C1-C6)alkyl, —O(C1-C6)alkyl, aryl and —NReRf, wherein any aryl of Z4 is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) groups selected from OH, halogen, —CF3, —OCF3, NO2, CN, (C1-C6)alkyl and —O(C1-C6)alkyl;
each Z5 is independently selected from OH, oxo, halogen, CF3, OCF3, NO2, CN, (C1-C6)alkyl, —O(C1-C6)alkyl, and —NRgRh;
Ra is selected from the group consisting of H, (C1-C6)alkyl and aryl(C1-C6)alkyl;
Rb is selected from the group consisting of H, (C1-C6)alkyl and aryl(C1-C6)alkyl;
Rc and Rd are each independently selected from H and (C1-C6)alkyl; or Rc and Rd together with the nitrogen to which they are attached form a piperidine, morpholine, piperazine, N-methylpiperazine or pyrrolidine;
Re and Rf are each independently selected from H and (C1-C6)alkyl; or Re and Rf together with the nitrogen to which they are attached form a piperidine, morpholine, piperazine, N-methylpiperazine or pyrrolidine; and
Rg and Rh are each independently selected from H and (C1-C6)alkyl; or Rg and Rh together with the nitrogen to which they are attached form a piperidine, morpholine, piperazine, N-methylpiperazine or pyrrolidine;
Ri is H or (C1-C6)alkyl; and
Rj is (C1-C6)alkyl;
or a salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein X is R1a(Ra)NC(O)—.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or claim 2 wherein Ra is H.

### Claim 4 (depends on 1)

The compound of claim 1 wherein X is R1aOC(O)—.

### Claim 5 (depends on 1)

The compound of claim 1 wherein X is R1bC(O)—.

### Claim 6 (depends on 1)

The compound of claim 1 wherein X is R1bS(O)2—.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6 wherein each R1a or R1b is independently (C1-C8)alkyl, (C3-C6)carbocyclyl or aryl(C1-C6)alkyl, wherein any (C1-C8)alkyl of R1a or R1b is optionally substituted with one or more Z3 groups and wherein any (C3-C6)carbocyclyl or aryl(C1-C6)alkyl of R1a or R1b is optionally substituted with one or more Z4 groups.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7 wherein each Z4 group is independently selected from (C1-C6)alkyl and aryl, wherein any aryl of Z4 is optionally substituted with one or more halogen.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6 wherein each R1a or R1b is independently propyl, butyl, pentyl, 2-methylpentyl, 2,5-dimethylhexyl, 2,2-dimethylpentyl, or phenylpropyl, 4-pentylcyclohexyl, 4-(prop-2-yl)cyclohexyl, 4-methylcyclohexyl or 4-(4-chlorophenyl)cyclohexyl.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6 wherein each R1a or R1b is independently prop-2-yl, but-2-yl, pent-3-yl, 4-methylpent-2-yl, 2,5-dimethylhex-3-yl, 4,4-dimethylpent-2-yl, 1-phenylprop-1-yl, 4-pentylcyclohexyl, 4-(prop-2-yl)cyclohexyl, 4-methylcyclohexyl or 4-(4-chlorophenyl)cyclohexyl.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10 wherein A1 is aryl(C1-C6)alkyl, wherein any aryl(C1-C6)alkyl of A1 is optionally substituted with one or more Z2 groups.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10 wherein A1 is aryl-CH2—, wherein any aryl-CH2— of A1 is optionally substituted with one or more Z2 groups.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10 wherein A1 is phenyl-CH2—.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The compound of any one of claims 1-13 wherein A2 is aryl(C1-C6)alkyl, wherein any aryl(C1-C6)alkyl of A2 is optionally substituted with one or more Z2 groups.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The compound of any one of claims 1-13 wherein A2 is aryl-CH2—, wherein any aryl-CH2— of A2 is optionally substituted with one or more Z2 groups.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The compound of any one of claims 1-13 wherein A2 is phenyl-CH2—.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16 wherein Y is —C(O)O—.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 1-17 wherein R4 is heteroaryl(C1-C6)alkyl, wherein any heteroaryl(C1-C6)alkyl of R4 is optionally substituted with one or more Z5 groups.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 1-17 wherein R4 is thiazolyl(C1-C6)alkyl, wherein thiazolyl(C1-C6)alkyl is optionally substituted with one or more Z5 groups.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 1-17 wherein R4 is thiazol-5-ylmethyl.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The compound of any one of claims 1-20 wherein R2 is H.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21 wherein R3 is H.

### Claim 23 (depends on 1)

The compound of claim 1 which is:
or a salt thereof.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A pharmaceutical composition comprising a compound of formula I of as described in any one of claims 1-23, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, further comprising one or more therapeutic agents metabolized by cyctochrome P450 monooxygenase.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25 wherein the therapeutic agents metabolized by cyctochrome P450 are selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, entry inhibitors, gp120 inhibitors, G6PD and NADH-oxidase inhibitors, CCR5 inhibitors, other drugs for treating HIV, interferons, ribavirin analogs, NS5b polymerase inhibitors, NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV and other drugs for treating HCV.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A method for improving the pharmacokinetics or increasing blood plasma levels of one or more therapeutic agents metabolized by cytochrome P450 monooxygenase, comprising co-administering to a patient treated with one or more therapeutic agents metabolized by cytochrome P450 monooxygenase, a pharmacokinetic improving or blood plasma level increasing effective amount of a compound of formula I as described in any one of claims 1-23, or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A compound of formula I as described in any one of claims 1-23, or a pharmaceutically acceptable salt thereof for use in medical therapy.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The use of a compound of formula I as described in any one of claims 1-23, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful for improving the pharmacokinetics of a therapeutic agent which is metabolized by cytochrome P450 monooxygenase or increasing the blood plasma levels of a therapeutic agent which is metabolized by cytochrome P450 monooxygenase.

### Claim 30 (depends on 29)

The use of claim 29 wherein the therapeutic agent metabolized by cytochrome P450 monooxygenase is selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, entry inhibitors, gp120 inhibitors, G6PD and NADH-oxidase inhibitors, CCR5 inhibitors, other drugs for treating HIV, interferons, ribavirin analogs, NS5b polymerase inhibitors, NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV and other drugs for treating HCV, and combinations thereof.
